Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or inhalation. A nasal COVID-19 vaccine, developed using technology from Washington ...

With the rise of omicron came the fall of long-lasting protection from reinfection with the pandemic coronavirus SARS-CoV-2, ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, ...

Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

For the week ending Jan. 25, seasonal flu activity remains high and increasing. Clinical laboratories tested 129,378 ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.